SAN DIEGO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of ...
Clinical proof of principle obtained in Phase I adjuvant head and neck cancer trial with individualized cancer vaccine TG4050 ̶ Further data on 24-month follow-up for all patients of the Phase I part ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to deliver novel immunotherapeutic proteins, ...
A personalized cell therapy that combines the strengths of tumour-infiltrating lymphocytes (TILs) with the benefits of chimeric antigen receptor (CAR) T cell therapies can shrink solid metastatic ...
Wave Life Sciences Ltd. (NASDAQ:WVE) stock is trading higher on Wednesday after the company revealed proof-of-mechanism data from the ongoing Phase 1b/2a RestorAATion-2 study of WVE-006 in alpha-1 ...
Parabilis Medicines Reports Positive Proof-of-Mechanism Data for Groundbreaking ERG Degrader Program
- Potent degradation of the transcription factor ERG demonstrated across three mouse models of ERG-fusion prostate cancer, correlating with substantial tumor growth inhibition - - First-in-class ...
Goto et al. 1 recently described a novel mechanism of immune evasion during the initial steps in the development of colorectal cancer in which nascent cancer cells reactivate a fetal program that is ...
A proof-of-concept trial by researchers at ETH Zurich, the University Hospitals of Basel and Zurich, and the Basel-Land Cantonal Hospital, demonstrated that treating breast cancer patients with a low, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results